Acute myeloid leukemia (AML) is an aggressive, heterogeneous disorder involving clonal expansion of progenitor myeloblasts in the bone marrow and peripheral blood. Research over the last decade has uncovered several recurrent somatic mutations associated with the disease biology. Hence, it may be increasingly important for labs to be able to efficiently profile AML samples for a growing number of diverse mutations, spanning single nucleotide variants, indels, tandem duplications, and gene fusions. During this presentation, Diana Morlote, assistant professor of pathology at the University of Alabama at Birmingham, will discuss the recent implementation of a rapid, automated next-generation sequencing (NGS) assay in her research laboratory for genomic profiling of AML and other related hematological disorders. The data collected from several cases using the Oncomine Myeloid Assay GX v2 by Thermo Fisher Scientific will be presented. Analytical performance will be discussed for various key mutations detected using DNA inputs. Morlote will describe how this solution addresses key challenges with molecular analysis of AML and other related malignancies. This research furthers our understanding of malignant hematological disorders and may lead to better care in the future.